A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
The purpose of the study is to test whether the combination of pembrolizumab and mRNA-4157 works better than just pembrolizumab to prevent your type of cancer from coming back. This study will also look at safety and tolerability, and whether mRNA-4157 and pembrolizumab have any effect on your immune system.
Stage III or IV melanoma which has been surgically removed.
1. Men and women 18 years or older
2. Stage III or IV Melanoma
3. Adequate organ function
4. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive study drug for about 1 year and visit the study site as instructed by the investigator and staff. After you stop the study drug, you will continue to be followed on the study for up to 3 years to see if your cancer has come back or spread.
Knight Clinical Trials Information Line